Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A narrative review summarizing the landscape of cellular therapies in sarcoma, reporting one FDA approval and describing early-stage investigational approaches without comparative efficacy data or quantified outcomes.
Single-center mechanistic study with small sample size (n=4 for single-cell analysis) characterizing HPV-specific T-cell populations; functional validation of TCRs supports hypothesis but lacks clinical endpoint data or comparative outcome analysis.